Biomarker Panel for Predicting Immunotherapy Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy treatments face challenges in predicting and managing immune-related adverse events (irAEs), which are unpredictable and can be severe, affecting up to 80% of patients, leading to significant morbidity and treatment interruptions, with limited biomarkers available to identify those at risk.
Innovation Solution
A method involving the assessment of chemokine and cytokine levels in human subjects, specifically using a panel of biomarkers such as MIF, CXCL16, CXCL8, CXCL9, CXCL10, CCL19, and CCL23, to predict immunotherapy toxicity, allowing for personalized treatment decisions and toxicity mitigation strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cancer immunotherapy is administered to expand treatment options, then treatment efficacy is improved, but immune-related adverse events increase
Solution Approach 1:
The patent applies preliminary action by measuring chemokine and cytokine levels in patient samples before initiating immunotherapy to predict which patients are at risk for immune-related adverse events. This allows clinicians to identify at-risk patients in advance and implement preventive strategies, such as enhanced monitoring or prophylactic treatments, before the adverse events occur, thereby maintaining treatment efficacy while reducing harm.
Solution Approach 2:
The patent implements feedback by using baseline chemokine and cytokine levels as biomarkers to predict toxicity risk, which then feeds back into treatment decision-making. Patients with elevated baseline levels can be identified as high-risk and receive adjusted treatment protocols, while those with normal levels continue with standard therapy. This feedback loop enables personalized treatment strategies that optimize efficacy while minimizing adverse events.
2Reliability
If patients with autoimmune disease are excluded from clinical trials, then safety is improved, but patient population coverage decreases
Solution Approach 1:
The patent applies parameter changes by shifting from a binary exclusion criterion (presence of autoimmune disease) to a continuous biomarker-based risk assessment (chemokine and cytokine levels). This allows for granular risk stratification, enabling clinicians to identify which patients with autoimmune histories are truly at risk versus those who may safely receive immunotherapy. The approach transforms safety determination from a categorical decision to a nuanced, quantifiable assessment.
Solution Approach 2:
The patent uses preliminary biomarker assessment to evaluate autoimmune risk before treatment initiation, allowing clinicians to make informed decisions about patient eligibility. Rather than automatically excluding all patients with autoimmune diseases, the baseline chemokine and cytokine measurements provide predictive information that guides individualized risk-benefit analysis, potentially expanding access to immunotherapy for previously excluded populations.
3Reliability
If treatment interruption occurs due to severe toxicity, then patient safety is improved, but treatment duration increases
Solution Approach 1:
The patent applies preliminary action by identifying patients at high risk for severe toxicity through baseline chemokine and cytokine measurements before treatment begins. This early risk stratification allows for proactive management strategies, such as enhanced monitoring schedules, prophylactic medications, or adjusted dosing protocols, designed specifically for high-risk patients. By preparing preventive measures in advance, the need for treatment interruptions is reduced, maintaining both safety and treatment continuity.
Solution Approach 2:
The patent implements feedback by using baseline biomarker levels to guide ongoing treatment management decisions. Patients identified as high-risk through elevated baseline chemokine and cytokine levels receive intensified monitoring and early intervention protocols. This feedback-driven approach enables timely detection and management of emerging toxicity, preventing severe adverse events that would require treatment interruption and thereby reducing overall treatment duration.
Data Source
AI summary
The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy—induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.